Genmab to Present at 27th Annual JPMorgan Healthcare Conference

Summary:  Genmab's CEO will present at the 27th Annual JPMorgan Healthcare      
Conference on January 14, 2009.                                                 

Copenhagen, Denmark; January 8, 2009 - Genmab A/S (OMX: GEN) announced today its
Chief Executive Officer, Lisa N. Drakeman, Ph.D., will present at the 27th      
Annual JPMorgan Healthcare Conference in San Francisco, California at 2:00PM    
local time on January 14, 2009.  The presentation will be available via live and
archived webcast at www.genmab.com.                                             


About Genmab A/S                                                                
Genmab is a leading international biotechnology company focused on developing   
fully human antibody therapeutics for the potential treatment of cancer.        
Genmab's world class discovery, development and manufacturing teams are using   
cutting-edge technology to create and develop products to address unmet medical 
needs.  Our primary goal is to improve the lives of patients who are in urgent  
need of new treatment options.  For more information on Genmab's products and   
technology, visit www.genmab.com.                                               

This press release contains forward looking statements. The words “believe”,    
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify    
forward looking statements. Actual results or performance may differ materially 
from any future results or performance expressed or implied by such statements. 
The important factors that could cause our actual results or performance to     
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical   
trials including unforeseen safety issues, uncertainties related to product     
manufacturing, the lack of market acceptance of our products, our inability to  
manage growth, the competitive environment in relation to our business area and 
markets, our inability to attract and retain suitably qualified personnel, the  
unenforceability or lack of protection of our patents and proprietary rights,   
our relationships with affiliated entities, changes and developments in         
technology which may render our products obsolete, and other factors. For a     
further discussion of these risks, please refer to the section “Risk Management”
in Genmab's Annual Report, which is available on www.genmab.com.  Genmab does   
not undertake any obligation to update or revise forward looking statements in  
this press release nor to confirm such statements in relation to actual results,
unless required by law.                                                         

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD20(R); HuMax-EGFr(TM);
HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-CD32b(TM)   
and UniBody(R) are all trademarks of Genmab A/S.                                

Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M: 
+45 25 27 47 13, E: hth@genmab.com                                              
                                                                                
Investor News No. 01/2009                                                       

###